Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Revenue Estimates
January 24, 2013 at 02:05 AM EST
Below are the top diagnostic substances stocks on the NASDAQ in terms of revenue estimate for the current year. Analysts expect IDEXX Laboratories (NASDAQ: IDXX ) to post revenue of $1.30 billion for the year ending December, 2012. IDEXX had $221.44 million in total cash for the latest quarter. Neogen (NASDAQ:
